Int J Mol Sci 22(23):12614
[2] The safety profile of Orforglipron was consistent with existing GLP-1 therapies, with the most common adverse events being mild to moderate gastrointestinal symptoms such as diarrhea, nausea, dyspepsia, and constipation
10.1093/cercor/bhab106 98
If your GLP-1 has stopped working, don't adjust the dose on your own
We want to strategically integrate behavioral health services wherever patients are receiving care. By treating the whole person and bringing behavioral health into every corner of healthcare, Wellstar is helping people take charge of their well-being in a way thats compassionate, connected and convenient
All medications carry potential risks and side effects that must be weighed against potential benefits in consultation with a physician